obsolete malignant soft tissue neoplasm of central nervous system

Obsolete Malignant Soft Tissue Neoplasm of Central Nervous System

The term "obsolete malignant soft tissue neoplasm of central nervous system" refers to a type of rare and aggressive tumor that originates from the soft tissues surrounding the brain and spinal cord. This term is considered obsolete, meaning it is no longer used in modern medical classification systems.

Characteristics:

• Malignant (cancerous) in nature
• Originates from soft tissues, such as nerves or connective tissue
• Located in the central nervous system (CNS), which includes the brain and spinal cord

Relevance:

This term is no longer used in modern medical classification systems, such as the World Health Organization (WHO) Classification of Tumors of the Central Nervous System. The WHO classification system has undergone significant updates, and this term is now considered outdated.

References:

• [1] - This term is listed as "obsolete" in various medical resources.
• [2-4] - These references confirm that this term is no longer used in modern medical classification systems.
• [5] - This source provides information on the characteristics of CNS tumors, but does not specifically mention this obsolete term.

Note: The information provided above is based on the search results and context provided.

Common Signs and Symptoms

The signs and symptoms of malignant soft tissue neoplasms of the central nervous system (CNS) can vary depending on the location and size of the tumor. However, some common symptoms include:

• Headache: A headache is often one of the first symptoms of a brain tumor, and it can be severe and persistent [3].
• Seizures: Seizures are another common symptom of brain tumors, especially in children [13].
• Weakness or numbness: Weakness or numbness in the face, arm, or leg can occur if the tumor is pressing on a nerve [1].
• Vision changes: Changes in vision, such as blurred vision, double vision, or loss of vision, can occur if the tumor is affecting the optic nerve [3].
• Personality changes: Personality changes, such as mood swings, depression, or anxiety, can occur if the tumor is affecting the emotional centers of the brain [1].

Other Symptoms

In addition to these common symptoms, other symptoms may include:

• Dizziness or loss of balance
• Nausea and vomiting
• Confusion or disorientation
• Memory problems
• Difficulty speaking or swallowing

It's worth noting that some of these symptoms can also be caused by other conditions, so a proper diagnosis from a medical professional is necessary to determine the cause.

References:

[1] by LB Nabors · 2013 - Most cases have multiple brain metastases evident on MRI scans. The presenting signs and symptoms of metastatic brain lesions are similar to those of other mass ...

[3] by A PERKINS · 2016 - The most common symptoms of these tumors are headache and seizures.

[13] by JB Guerin · 2023 - This review will focus on new or revised CNS tumor types other than infiltrating glioma, with an emphasis on imaging features and changes relevant to radiology ...

Based on the provided context, it appears that there are no specific diagnostic tests mentioned for an "obsolete" malignant soft tissue neoplasm of the central nervous system. However, I can provide some general information on diagnostic tests related to soft tissue tumors and CNS tumors.

Diagnostic tests for soft tissue tumors may include:

• Magnetic Resonance Imaging (MRI) [12]
• Clinical assessment
• Laboratory tests such as EEG and spinal tap [7]

For CNS tumors, the following diagnostic tests are mentioned in the context:

• Histologic, cytologic, radiographic, or clinical diagnosis of a malignant neoplasm [4]
• DNA methylation profile aligned with CNS neuroblastoma, FOXR2 activated confirms the diagnosis [5]
• Tumor biomarkers exist in tumor tissues or body fluids such as blood, urine, stool, saliva, and are produced by the tumor or the body's response to the tumor [6]

It is worth noting that the context mentions that "tumors from a number of primary sites" including soft tissue tumors have been reclassified, but it does not provide specific information on diagnostic tests for an obsolete malignant soft tissue neoplasm of the CNS.

However, based on general knowledge, some diagnostic tests that may be relevant to soft tissue tumors and CNS tumors include:

• Biopsy: a surgical procedure in which a sample of tissue is taken from a suspected tumor [7]
• Molecular testing such as next-generation sequencing (NGS) gene panels for brain tumors and methylation profiling [10]

Please note that these are general diagnostic tests and may not be specific to an "obsolete" malignant soft tissue neoplasm of the CNS.

References:

[4] Note 4: There must be a histologic, cytologic, radiographic, or clinical diagnosis of a malignant neoplasm /3. [5] For unresolved lesions a DNA methylation profile aligned with CNS neuroblastoma, FOXR2 activated confirms the diagnosis. [6] Tumor biomarkers exist in tumor tissues or body fluids such as blood, urine, stool, saliva, and are produced by the tumor or the body's response to the tumor. [7] Laboratory tests include the EEG and the spinal tap. A biopsy, a surgical procedure in which a sample of tissue is taken from a suspected tumor, helps doctors ... [10] Several methods are used in molecular testing; however, WHO CNS5 does not recommend any specific methods [].In molecular characterising of CNS tumors, next-generation sequencing (NGS) gene panels for brain tumors and methylation profiling have become very useful and efficient [22, 39].

Based on the provided context, it appears that there are various rare and obsolete malignant soft tissue neoplasms affecting the central nervous system (CNS). While modern treatment options may have evolved, I'll summarize the available information on drug treatments for these specific conditions.

Historical Context In the past, certain types of malignant soft tissue tumors were more prevalent in the CNS. These include:

• PNETs (Primitive Neuroectodermal Tumors): Although rare, PNETs are infrequent in children and very rare in adults, with an overall incidence of 0.26 per 100,000 person-years reported by the Central Brain Tumor Registry of the United States [1].
• PEComas: These tumors were FDA-approved for adult patients with locally advanced unresectable or metastatic malignant PEComa in November 2021 [2].

Drug Treatments While modern treatment options may have shifted towards more targeted therapies, some older treatments are still relevant:

• Anthracycline-based cytotoxic chemotherapy: This remains a first-line therapy for most advanced or metastatic soft tissue sarcomas (STS) [3].
• Carmustine injection: The treatment regimen involves 150 to 200 mg/m2 intravenously over at least 2 hours, repeated every 6 weeks [4].

Current Treatment Landscape It's essential to note that the current treatment landscape for CNS tumors has evolved significantly. Modern therapies often involve a multidisciplinary approach, including surgery, radiation therapy, and targeted treatments.

However, based on the provided context, it appears that some older drug treatments may still be relevant for specific types of malignant soft tissue neoplasms affecting the CNS.

References

[1] The WHO classification system further divided these tumors into histologic variants. [5] [2] nab-sirolimus was FDA approved for adult patients with locally advanced unresectable or metastatic malignant PEComa in November 2021 [6] [3] First line therapy for most advanced or metastatic STS remains anthracycline-based cytotoxic chemotherapy. [7] [4] For carmustine injection, the treatment regimen involves 150 to 200 mg/m2 intravenously over at least 2 hours, repeated every 6 weeks [8]

Please note that this information is based on a historical context and may not reflect current standard practices or guidelines.

The differential diagnosis of an obsolete malignant soft tissue neoplasm of the central nervous system (CNS) involves considering various types of tumors that can arise in this region.

According to [3], a guideline for diagnosis and treatment of rare CNS embryonal and sarcomatous tumours and astroblastoma, MN1-altered, the differential diagnosis includes:

• Malignant lesions such as primary or metastatic carcinoma, melanoma, and other types of cancer
• Soft tissue tumors like rhabdomyosarcoma, which is a malignant counterpart that can occur in children [15]
• Other CNS embryonal tumors, classified into two groups: medulloblastoma and other CNS embryonal tumors (the term “primitive neuroectodermal tumor” or PNET) [4]

Additionally, the diagnosis of soft tissue tumors is challenging due to their diversity and histological overlap among tumor entities [13]. The molecular pathogenesis of soft tissue tumors has rapidly increased with the development of molecular genetic techniques.

In terms of specific CNS soft tissue neoplasms, myxofibrosarcoma is a malignant tumor that tends to arise in the superficial soft tissue of the extremities, particularly the lower extremities, of older adults [12]. However, it's worth noting that this information might not be directly relevant to an obsolete malignant soft tissue neoplasm of the CNS.

It's also important to consider other types of tumors that can occur in the CNS, such as gliomas and meningiomas. However, these are typically not classified as soft tissue neoplasms.

In summary, the differential diagnosis of an obsolete malignant soft tissue neoplasm of the CNS involves considering various types of tumors that can arise in this region, including malignant lesions, soft tissue tumors, and other CNS embryonal tumors.

References:

[3] This document is intended as a guideline for diagnosis and treatment of rare CNS embryonal and sarcomatous tumours and astroblastoma, MN1-altered. [4] by AG Osborn · 2022 · Cited by 145 — The 2021 WHO classifies CNS embryonal tumors into 2 groups: medulloblastoma and other CNS embryonal tumors (the term “primitive neuroectodermal ... [12] Myxofibrosarcoma is a malignant tumor of fibroblastic differentiation that tends